{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,18]],"date-time":"2026-08-18T04:34:33Z","timestamp":1787027673440,"version":"build-2736575974"},"reference-count":27,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2021,11,1]],"date-time":"2021-11-01T00:00:00Z","timestamp":1635724800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2021,11,1]],"date-time":"2021-11-01T00:00:00Z","timestamp":1635724800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2021,11,1]],"date-time":"2021-11-01T00:00:00Z","timestamp":1635724800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2021,11,1]],"date-time":"2021-11-01T00:00:00Z","timestamp":1635724800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2021,11,1]],"date-time":"2021-11-01T00:00:00Z","timestamp":1635724800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2021,11,1]],"date-time":"2021-11-01T00:00:00Z","timestamp":1635724800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2021,11,1]],"date-time":"2021-11-01T00:00:00Z","timestamp":1635724800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Affective Disorders"],"published-print":{"date-parts":[[2021,11]]},"DOI":"10.1016\/j.jad.2021.07.035","type":"journal-article","created":{"date-parts":[[2021,7,20]],"date-time":"2021-07-20T01:23:21Z","timestamp":1626744201000},"page":"592-596","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":20,"special_numbering":"C","title":["The meaningful change threshold as measured by the 16-item quick inventory of depressive symptomatology in adults with treatment-resistant major depressive and bipolar disorder receiving intravenous ketamine"],"prefix":"10.1016","volume":"294","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-4733-2523","authenticated-orcid":false,"given":"Roger S.","family":"McIntyre","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9110-7951","authenticated-orcid":false,"given":"Orly","family":"Lipsitz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Leanna M.W.","family":"Lui","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nelson B.","family":"Rodrigues","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3568-8816","authenticated-orcid":false,"given":"Hartej","family":"Gill","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Flora","family":"Nasri","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3969-8333","authenticated-orcid":false,"given":"Rui","family":"Ling","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kayla M.","family":"Teopiz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Roger C.","family":"Ho","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mehala","family":"Subramaniapillai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kevin","family":"Kratiuk","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rodrigo B.","family":"Mansur","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3248-1059","authenticated-orcid":false,"given":"Brett D.M.","family":"Jones","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yena","family":"Lee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joshua D.","family":"Rosenblat","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jad.2021.07.035_bib0001","doi-asserted-by":"crossref","first-page":"257","DOI":"10.1016\/j.comppsych.2008.08.005","article-title":"The Clinical Global Impressions scale: errors in understanding and use","volume":"50","author":"Busner","year":"2009","journal-title":"Compr. Psychiatry"},{"key":"10.1016\/j.jad.2021.07.035_bib0002","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1007\/s11136-017-1616-3","article-title":"Moving from significance to real-world meaning: methods for interpreting change in clinical outcome assessment scores","volume":"27","author":"Coon","year":"2018","journal-title":"Qual. Life Res."},{"key":"10.1016\/j.jad.2021.07.035_bib0003","first-page":"1","article-title":"A clinical approach to treatment resistance in depressed patients: what to do when the usual treatments don't work well enough?","author":"Dodd","year":"2020","journal-title":"World J. Biol. Psychiatry"},{"key":"10.1016\/j.jad.2021.07.035_bib0004","doi-asserted-by":"crossref","first-page":"970","DOI":"10.1016\/j.jad.2020.07.109","article-title":"The concept and management of acute episodes of treatment-resistant bipolar disorder: a systematic review and exploratory meta-analysis of randomized controlled trials","volume":"276","author":"Fornaro","year":"2020","journal-title":"J. Affect. Disord."},{"key":"10.1016\/j.jad.2021.07.035_bib0005","author":"Hudgens","year":"2020","journal-title":"J. Affect. Disord."},{"key":"10.1016\/j.jad.2021.07.035_bib0006","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1097\/JCP.0000000000001317","article-title":"A systematic review on the efficacy of intravenous racemic ketamine for bipolar depression","volume":"41","author":"Joseph","year":"2021","journal-title":"J. Clin. Psychopharmacol."},{"key":"10.1016\/j.jad.2021.07.035_bib0007","doi-asserted-by":"crossref","first-page":"82","DOI":"10.1016\/j.jad.2019.02.005","article-title":"Subtypes of treatment-resistant depression determined by a latent class analysis in a Chinese clinical population","volume":"249","author":"Liao","year":"2019","journal-title":"J. Affect. Disord."},{"key":"10.1016\/j.jad.2021.07.035_bib0008","doi-asserted-by":"crossref","first-page":"831","DOI":"10.1016\/j.jad.2020.09.007","article-title":"A systematic review and meta-analysis of the efficacy of intravenous ketamine infusion for treatment resistant depression: January 2009 - January 2019","volume":"277","author":"Marcantoni","year":"2020","journal-title":"J. Affect. Disord."},{"key":"10.1016\/j.jad.2021.07.035_bib0009","doi-asserted-by":"crossref","first-page":"657","DOI":"10.1111\/bdi.13026","article-title":"In vivo phenotyping, mechanism-informed treatments, domain-based psychopathology and nomological networks: a strategy for treatment discovery and development in bipolar depression","volume":"22","author":"McIntyre","year":"2020","journal-title":"Bipolar Disord."},{"key":"10.1016\/j.jad.2021.07.035_bib0010","first-page":"1841","volume":"396","author":"McIntyre","year":"2020","journal-title":"Bipolar Disord. Lancet"},{"key":"10.1016\/j.jad.2021.07.035_bib0011","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.jad.2013.10.043","article-title":"Treatment-resistant depression: definitions, review of the evidence, and algorithmic approach","volume":"156","author":"McIntyre","year":"2014","journal-title":"J. Affect. Disord."},{"key":"10.1016\/j.jad.2021.07.035_bib0012","doi-asserted-by":"crossref","first-page":"831","DOI":"10.1111\/bdi.12941","article-title":"The effectiveness of ketamine on anxiety, irritability, and agitation: implications for treating mixed features in adults with major depressive or bipolar disorder","volume":"22","author":"McIntyre","year":"2020","journal-title":"Bipolar Disord."},{"key":"10.1016\/j.jad.2021.07.035_bib0013","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1016\/j.jad.2020.07.045","article-title":"Burden of Treatment Resistant Depression (TRD) in patients with major depressive disorder in Ontario using Institute for Clinical Evaluative Sciences (ICES) databases: Economic burden and healthcare resource utilization","volume":"277","author":"McIntyre","year":"2020","journal-title":"J. Affect. Disord."},{"key":"10.1016\/j.jad.2021.07.035_bib0014","doi-asserted-by":"crossref","first-page":"903","DOI":"10.1016\/j.jad.2020.05.088","article-title":"The effectiveness of repeated intravenous ketamine on depressive symptoms, suicidal ideation and functional disability in adults with major depressive disorder and bipolar disorder: results from the Canadian rapid treatment center of excellence","volume":"274","author":"McIntyre","year":"2020","journal-title":"J. Affect. Disord."},{"key":"10.1016\/j.jad.2021.07.035_bib0015","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1016\/j.eurpsy.2018.05.006","volume":"53","author":"Mohebbi","year":"2018","journal-title":"Eur. Psychiatry"},{"key":"10.1016\/j.jad.2021.07.035_bib0016","doi-asserted-by":"crossref","DOI":"10.4088\/JCP.19r12889","article-title":"Efficacy of esketamine augmentation in major depressive disorder: a meta-analysis","volume":"81","author":"Papakostas","year":"2020","journal-title":"J. Clin. Psychiatry"},{"key":"10.1016\/j.jad.2021.07.035_bib0017","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1017\/S1092852919001159","article-title":"Keeping up with the clinical advances: depression","volume":"24","author":"Ragguett","year":"2019","journal-title":"CNS Spectr."},{"key":"10.1016\/j.jad.2021.07.035_bib0018","doi-asserted-by":"crossref","first-page":"102","DOI":"10.1016\/j.jclinepi.2007.03.012","article-title":"Recommended methods for determining responsiveness and minimally important differences for patient-reported outcomes","volume":"61","author":"Revicki","year":"2008","journal-title":"J. Clin. Epidemiol."},{"key":"10.1016\/j.jad.2021.07.035_bib0019","first-page":"1","article-title":"Safety and tolerability of IV ketamine in adults with major depressive or bipolar disorder: results from the Canadian rapid treatment center of excellence","author":"Rodrigues","year":"2020","journal-title":"Expert Opin. Drug Saf."},{"key":"10.1016\/j.jad.2021.07.035_bib0020","article-title":"Factors that impact treatment decisions: results from an online survey of individuals with bipolar and unipolar depression","volume":"20","author":"Rosenblat","year":"2018","journal-title":"Prim. Care Companion CNS Disord."},{"key":"10.1016\/j.jad.2021.07.035_bib0021","doi-asserted-by":"crossref","first-page":"573","DOI":"10.1016\/S0006-3223(02)01866-8","article-title":"The 16-item quick inventory of depressive symptomatology (QIDS), clinician rating (QIDS-C), and self-report (QIDS-SR): a psychometric evaluation in patients with chronic major depression","volume":"54","author":"Rush","year":"2003","journal-title":"Biol. Psychiatry"},{"key":"10.1016\/j.jad.2021.07.035_bib0022","doi-asserted-by":"crossref","first-page":"e18","DOI":"10.4088\/JCP.8133tx4c","article-title":"Treatment-resistant depression: prevalence, risk factors, and treatment strategies","volume":"72","author":"Thase","year":"2011","journal-title":"J. Clin. Psychiatry"},{"issue":"Suppl 13","key":"10.1016\/j.jad.2021.07.035_bib0023","first-page":"23","article-title":"When at first you don't succeed: sequential strategies for antidepressant nonresponders","volume":"58","author":"Thase","year":"1997","journal-title":"J. Clin. Psychiatry"},{"key":"10.1016\/j.jad.2021.07.035_bib0024","article-title":"Clinically meaningful changes on depressive symptom measures and patient-reported outcomes in patients with treatment-resistant depression","author":"Turkoz","year":"2020","journal-title":"Acta Psychiatr. Scand."},{"key":"10.1016\/j.jad.2021.07.035_bib0025","series-title":"Guidance for Industry Patient-Reported Outcome Measures: Use in Medical Product Development to Support Labeling Claims","year":"2009"},{"key":"10.1016\/j.jad.2021.07.035_bib0026","article-title":"The acute antisuicidal effects of single-dose intravenous ketamine and intranasal esketamine in individuals with major depression and bipolar disorders: a systematic review and meta-analysis","author":"Xiong","year":"2020","journal-title":"J. Psychiatr. Res."},{"key":"10.1016\/j.jad.2021.07.035_bib0027","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1159\/000499917","article-title":"Have treatment studies of depression become even less generalizable? Applying the inclusion and exclusion criteria in placebo-controlled antidepressant efficacy trials published over 20 years to a clinical sample","volume":"88","author":"Zimmerman","year":"2019","journal-title":"Psychother. Psychosom."}],"container-title":["Journal of Affective Disorders"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S016503272100714X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S016503272100714X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,28]],"date-time":"2025-09-28T02:32:36Z","timestamp":1759026756000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S016503272100714X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,11]]},"references-count":27,"alternative-id":["S016503272100714X"],"URL":"https:\/\/doi.org\/10.1016\/j.jad.2021.07.035","relation":{},"ISSN":["0165-0327"],"issn-type":[{"value":"0165-0327","type":"print"}],"subject":[],"published":{"date-parts":[[2021,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"The meaningful change threshold as measured by the 16-item quick inventory of depressive symptomatology in adults with treatment-resistant major depressive and bipolar disorder receiving intravenous ketamine","name":"articletitle","label":"Article Title"},{"value":"Journal of Affective Disorders","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jad.2021.07.035","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2021 Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}]}}